| Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study RL Carhart-Harris, M Bolstridge, J Rucker, CMJ Day, D Erritzoe, M Kaelen, ... The Lancet Psychiatry 3 (7), 619-627, 2016 | 1741 | 2016 |
| Psilocybin with psychological support for treatment-resistant depression: six-month follow-up RL Carhart-Harris, M Bolstridge, CMJ Day, J Rucker, R Watts, DE Erritzoe, ... Psychopharmacology 235, 399-408, 2018 | 1062 | 2018 |
| Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier CI Grainger, LL Greenwell, DJ Lockley, GP Martin, B Forbes Pharmaceutical research 23, 1482-1490, 2006 | 446 | 2006 |
| Hyaluronan: pharmaceutical characterization and drug delivery YH Liao, SA Jones, B Forbes, GP Martin, MB Brown Drug delivery 12 (6), 327-342, 2005 | 440 | 2005 |
| Human respiratory epithelial cell culture for drug delivery applications B Forbes, C Ehrhardt European journal of pharmaceutics and biopharmaceutics 60 (2), 193-205, 2005 | 384 | 2005 |
| Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro A Grenha, CI Grainger, LA Dailey, B Seijo, GP Martin, C Remuñán-López, ... European Journal of Pharmaceutical Sciences 31 (2), 73-84, 2007 | 293 | 2007 |
| Human airway epithelial cell lines for in vitro drug transport and metabolism studies B Forbes Pharmaceutical science & technology today 3 (1), 18-27, 2000 | 221 | 2000 |
| The human bronchial epithelial cell line 16HBE14o− as a model system of the airways for studying drug transport B Forbes, A Shah, GP Martin, AB Lansley International journal of pharmaceutics 257 (1-2), 161-167, 2003 | 195 | 2003 |
| In vitro models of inhalation toxicity and disease K BeruBe, M Aufderheide, D Breheny, R Clothier, R Combes, R Duffin, ... Alternatives to laboratory animals 37 (1), 89-141, 2009 | 179 | 2009 |
| Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience FA Stressmann, GB Rogers, CJ Van Der Gast, P Marsh, LS Vermeer, ... Thorax 67 (10), 867-873, 2012 | 169 | 2012 |
| In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits ST Lim, B Forbes, DJ Berry, GP Martin, MB Brown International journal of pharmaceutics 231 (1), 73-82, 2002 | 163 | 2002 |
| Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? FA Stressmann, GB Rogers, P Marsh, AK Lilley, TWV Daniels, MP Carroll, ... Journal of Cystic Fibrosis 10 (5), 357-365, 2011 | 161 | 2011 |
| Challenges in inhaled product development and opportunities for open innovation B Forbes, B Asgharian, LA Dailey, D Ferguson, P Gerde, M Gumbleton, ... Advanced drug delivery reviews 63 (1-2), 69-87, 2011 | 149 | 2011 |
| Mycobacteria-specific cytokine responses detect tuberculosis infection and distinguish latent from active tuberculosis M Tebruegge, B Dutta, S Donath, N Ritz, B Forbes, K Camacho-Badilla, ... American journal of respiratory and critical care medicine 192 (4), 485-499, 2015 | 147 | 2015 |
| Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles AC Silva, A Kumar, W Wild, D Ferreira, D Santos, B Forbes International journal of pharmaceutics 436 (1-2), 798-805, 2012 | 147 | 2012 |
| Nail swelling as a pre-formulation screen for the selection and optimisation of ungual penetration enhancers RH Khengar, SA Jones, RB Turner, B Forbes, MB Brown Pharmaceutical Research 24, 2207-2212, 2007 | 123 | 2007 |
| Regulation, risk and safety of faecal microbiota transplant B Merrick, L Allen, NMM Zain, B Forbes, DL Shawcross, SD Goldenberg Infection prevention in practice 2 (3), 100069, 2020 | 110 | 2020 |
| Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs P Bäckman, S Arora, W Couet, B Forbes, W de Kruijf, A Paudel European Journal of Pharmaceutical Sciences 113, 41-52, 2018 | 106 | 2018 |
| Overcoming the nail barrier: a systematic investigation of ungual chemical penetration enhancement MB Brown, RH Khengar, RB Turner, B Forbes, MJ Traynor, CRG Evans, ... International journal of pharmaceutics 370 (1-2), 61-67, 2009 | 106 | 2009 |
| Double optimization of rivastigmine-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery using the quality by design (QbD) approach: formulation variables and … S Cunha, CP Costa, JA Loureiro, J Alves, AF Peixoto, B Forbes, ... Pharmaceutics 12 (7), 599, 2020 | 105 | 2020 |
